InvestingPro's Fair Value analysis flagged Prestige Consumer Healthcare Inc. (NYSE: PBH) as significantly overvalued in February 2025, when shares traded at $86.12, according to the source. The platform calculated a Fair Value of $50.69, which implied the stock was overpriced by about 41%.

The source reports that the stock fell to a low of $45.64 in October 2026, a 46% decline from the February 2025 price. As of November 15, 2026, shares traded at $46.19, the source says.

The source reports that Prestige's revenue rose modestly to $1.17 billion, while EBITDA fell to $345 million from $361 million. Earnings per share fell to $3.26 from $4.30, a 24% decrease. The source attributes supply chain challenges to the revenue pressure. It also says Jefferies lowered its price target to $51, citing uncertainty around the Clear Eyes product line.

The source also notes that Prestige completed a $150 million acquisition of LaCorium and a $400 million notes offering.

The article is promotional. It promotes InvestingPro's tools and describes its Fair Value methodology, but it does not provide the model's inputs or independent verification of its results. The source's claim that the analysis "validated" the decline reflects the publisher's framing.